You will need to have regular blood tests and check-ups during your treatment with hydroxycarbamide. The blood tests are important as a way of monitoring your treatment, and also to check that ...
Pfizer voluntarily withdraws all lots of sickle cell disease treatment Oxbryta from worldwide markets: New York Friday, September 27, 2024, 10:00 Hrs [IST] Pfizer Inc. announced t ...
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease ...
NEW YORK, September 25, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell ...
We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...
Cost-effectiveness agency NICE has issued final draft guidance on Oxbryta (voxelotor) that clears the way for the use of the drug – with or without hydroxycarbamide – as an option for treating ...
We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...